Axicabtagene Ciloleucel & Brexucabtagene Autoleucel

Scientific Name	Axicabtagene Ciloleucel & Brexucabtagene Autoleucel
Brand Name	Yescarta & Tecartus
Risk	Potential risk of T-cell malignancy associated with the use of chimeric antigen receptor (CAR) T cell Immunotherapies Secondary malignancies of T-cell origin, including chimeric antigen receptor (CAR)- positive malignancies, have been reported within weeks and up to several years following treatment of haematological malignancies with a BCMA- or CD19-directed CAR T-cell therapy. Patients should be monitored life-long for secondary malignancies.
Educational Materials for Healthcare Professionals	Download Download
Dear Healthcare Professional Communication (DHPC) for Healthcare Professionals	Download
Safety Communication for Healthcare Professionals	Download Download

Share page